Payment overview · 2025
General Payments
$2,160.45
145 reported records · 26 companies
Healthcare provider profile · identity verified
Amanda Combs, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · RICHLANDS, VA · NPI 1881133585
Verified facts
What the public records show
CMS Open Payments records show Amanda Combs, NP-C received $2,160.45 in general payments during 2025 across 145 reported records.
ABBVIE INC. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $410.07 | 19.0% | 43 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $311.44 | 14.4% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $175.90 | 8.1% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.81 | 8.1% | 26 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $163.53 | 7.6% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.16 | 6.6% | 9 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $103.30 | 4.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.22 | 4.5% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.06 | 4.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $64.89 | 3.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.61 | 2.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.96 | 2.1% | 2 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $43.34 | 2.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $37.40 | 1.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.35 | 1.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.03 | 1.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.80 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.91 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.07 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.94 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.72 | 0.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.45 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.24 | 0.8% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $16.12 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.93 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.20 | 0.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,160.45 | 145 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $311.44 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $244.94 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $243.84 | 19 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $163.53 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $146.24 | 21 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $113.65 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $113.65 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $113.47 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $110.62 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.62 | 18 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $103.30 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $98.22 | 5 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $98.22 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $86.06 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.51 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $64.89 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.19 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $46.87 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.63 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.96 | 2 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $43.34 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.08 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.08 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.51 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.35 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.35 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.20 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 152 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 110 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 105 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
105 | 21 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
110 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 466 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 99 |
| Lisinopril | Lisinopril | 363 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 83 |
| Omeprazole | Omeprazole | 328 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 288 | 50 |
| Gabapentin | Gabapentin | 268 | 44 |
| Losartan Potassium | Losartan Potassium | 259 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 75 |
| Montelukast Sodium | Montelukast Sodium | 240 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 226 | 60 |
| Furosemide | Furosemide | 223 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 55 |
| Metformin Hcl | Metformin Hcl | 210 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 189 | 52 |
| Eliquis | Apixaban | 152 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 35 |
| Ozempic | Semaglutide | 128 | 22 |
| Famotidine | Famotidine | 127 | 35 |
| Meloxicam | Meloxicam | 123 | 32 |
| Alprazolam | Alprazolam | 122 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 17 |
| Tramadol Hcl | Tramadol Hcl | 120 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 38 |
| Mounjaro | Tirzepatide | 110 | 22 |
| Sertraline Hcl | Sertraline Hcl | 110 | 33 |
| Trazodone Hcl | Trazodone Hcl | 110 | 27 |
| Potassium Chloride | Potassium Chloride | 107 | 29 |
| Clonazepam | Clonazepam | 105 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 21 |
| Allopurinol | Allopurinol | 102 | 21 |
| Fluconazole | Fluconazole | 100 | 44 |
| Ondansetron Odt | Ondansetron | 99 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 24 |
| Atenolol | Atenolol | 94 | 26 |
| Simvastatin | Simvastatin | 94 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 21 |
| Finasteride | Finasteride | 90 | 24 |
| Lorazepam | Lorazepam | 89 | 17 |
| Pregabalin | Pregabalin | 88 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 19 |
| Carvedilol | Carvedilol | 81 | 22 |
| Prednisone | Prednisone | 80 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 17 |
| Bupropion Xl | Bupropion Hcl | 74 | 17 |
| Farxiga | Dapagliflozin Propanediol | 74 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 13 |
| Buspirone Hcl | Buspirone Hcl | 70 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 70 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 55 |
| Celecoxib | Celecoxib | 67 | 12 |
| Methocarbamol | Methocarbamol | 66 | 25 |
| Methylprednisolone | Methylprednisolone | 66 | 53 |
| Linzess | Linaclotide | 65 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 12 |
| Propranolol Hcl | Propranolol Hcl | 61 | 14 |
| Baclofen | Baclofen | 59 | 13 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Ezetimibe | Ezetimibe | 58 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 47 |
| Azithromycin | Azithromycin | 52 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Jardiance | Empagliflozin | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 45 | 11 |
| Valsartan | Valsartan | 45 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 22 |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Nystatin | Nystatin | 41 | 20 |
| Spironolactone | Spironolactone | 41 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 12 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 33 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 13 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 30 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 12 |
| Torsemide | Torsemide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 21 | 13 |
| Diazepam | Diazepam | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Cephalexin | Cephalexin | 16 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,160.45 · 145 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, DUPIXENT, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, HETLIOZ, Kerendia, LEQVIO, LINZESS, MOUNJARO, NEMLUVIO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, Quviviq, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error